MedTrace Logo

Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Colonosopy

NCT03466632 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-03-15

No results posted yet for this study

Summary

Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy

Conditions

  • Colonic Diseases

Interventions

DRUG

Propofol

propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure.

DRUG

Dexmedetomidine

dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Sherief Abd-Elsalam, MD · Tanta University

  • Sameh Abdelkhalek Ahmed, MD · Tanta University Anasthesia Department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-01
Primary Completion
2020-04-01
Completion
2020-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03466632 on ClinicalTrials.gov